Alunbrig 30 mg film-coated tablets

DRUG4 trials

Sponsors

Intergroupe Francophone De Cancerologie Thoracique, Fundacion GECP, Prinses Maxima Centrum voor Kinderoncologie B.V., Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Conditions

ALK+ NSCLCALK+ non-small cell lung cancerAnaplastic Large Cell Lymphoma (ALCL)Inflammatory Myofibroblastic Tumors (IMT)Other solid tumorsadvanced ALK-positive non-small cell lung cancerlocally advanced (stage III) and not suitable for curative treatmentor metastatic (stage IV) ALK+ NSCLC

Phase 1

A Phase I/II study of Brigatinib in pediatric and young adult patients with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or other solid tumors

RecruitingCTIS2024-513412-10-00

Prinses Maxima Centrum voor Kinderoncologie B.V.Anaplastic Large Cell Lymphoma (ALCL), Inflammatory Myofibroblastic Tumors (IMT), Other solid tumors

Start: 2022-05-11Target: 54Updated: 2025-12-09

Phase 2

IFCT-2101 MASTERPROTOCOL ALK A phase II randomized, open-labelled, multicenter study of safety and efficacy of brigatinib and carboplatin-pemetrexed combination therapy or brigatinib monotherapy as first-line treatment in patients with advanced ALK-positive non-small cell lung cancer

Active, not recruitingCTIS2023-510387-13-00

Intergroupe Francophone De Cancerologie Thoraciqueadvanced ALK-positive non-small cell lung cancer

Start: 2022-05-18Target: 110Updated: 2025-02-11

Clinical Utility of Liquid Biopsy as a tool to assess the evolution of brigatinib treated patients with non-small cell lung cancer with EML4-ALK translocation: an exploratory study (CUBIK)

Active, not recruitingCTIS2024-511317-38-00

Fundacion GECPALK+ non-small cell lung cancer

Start: 2020-05-04Target: 33Updated: 2025-12-18

ABP - Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping

Active, not recruitingCTIS2024-513947-94-00

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbHALK+ NSCLC, locally advanced (stage III) and not suitable for curative treatment, or metastatic (stage IV) ALK+ NSCLC

Start: 2020-03-30Target: 118Updated: 2025-12-17